#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Peroral antidiabetics and thyroid diseases


Authors: Štefan Sotak
Authors‘ workplace: I. interná klinika LF UPJŠ a UNLP Košice
Published in: Diab Obez 2020; 20(39): 42-46
Category: Reviews

Overview

Thyroid diseases and type 2 diabetes mellitus are the two most common endocrinological diseases worldwide. The relationship between type 1 diabetes mellitus and thyroid diseases is known and described, but the relationship between thyreopathies and type 2 diabetes is not clarified sufficiently through that studies manifest increasingly the connection between them. Diabetes also can affect thyroid gland function indirectly by some peroral antidiabetics.

Keywords:

metformin – type 2 diabetes mellitus – peroral antidiabetics – thyroid diseases


Sources
  1. Buse JB, Polonsky KS, Burant CF. Type 2 Diabetes Mellitus. In: Melmed S, Polonsky KS, Larsen PR et al. Williams Textbook of Endocrinology. Elsevier: Philadelphia 2010: 1329–1358. ISBN 978–14–3770–324–5.
  2. Vondra K, Vrbíková J, Zamrazil V. Diabetes mellitus a onemocnení štítné žlázy. In: Stárka L et al. Pokroky v endokrinologii. Maxdorf: Praha 2007: 656–668. ISBN 978–80–7345–129–5.
  3. Pelikánová T. Endokrinný pankreas a diabetes mellitus. In: Kreze A, Langer P, Klimeš I et al. Všeobecná a klinická endokrinológia. Academic Electronic Press: Bratislava 2004: 567–750. ISBN 80–88880–58–0.
  4. Hage M, Zantout MS, Azar ST. Thyroid Disorders and Diabetes Mellitus. J Thyroid Res 2011; 2011: 439463. Dostupné z DOI: <http://dx.doi.org/10.4061/2011/439463>.
  5. Chen TM, Lin CC, Huang PT et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011; 26(5): 858–865. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1440–1746.2011.06664.x>.
  6. Díez JJ, Sánchez P, Iglesias P. Prevalence of thyroid dysfunction in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011; 119(4): 201–207. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0031–1271691>.
  7. Al-Attas OS, Al-Daghri NM, Alkharfy KM et al. Urinary iodine is associated with insulin resistance in subjects with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes 2012; 120(10): 618–622. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0032–1323816>.
  8. Díez JJ, Iglesias P. Subclinical hyperthyroidism in patients with type 2 diabetes. Endocrine 2012; 42(1): 157–163. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0031–1271691>.
  9. Kouidhi S, Berhouma R, Ammar M et al. Relationship of thyroid function with obesity and type 2 diabetes in euthyroid Tunisian subjects. Endocr Res 2013; 38(1): 15–23. Dostupné z DOI: <http://dx.doi.org/10.3109/07435800.2012.699987>.
  10. Sousa Vergara Palma CC, Pavesi M, Guedes Nogueira V et al. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetol Metab Syndr 2013; 5: 58. Dostupné z DOI: <http://dx.doi.org/10.1186/1758–5996–5-58>.
  11. Balkan F, Onal ED, Usluogullari A et al. Is there any association between insulin resistance and thyroid cancer? A case control study. Endocrine 2014; 45(1): 55–60. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–013–9942-x>.
  12. Sotak Š, Lazúrová I, Felšőci M. Výskyt diabetes mellitus 2. typu u pacientov s autoimunitnou tyroiditídou v štádiu hypotyreózy. Vnit Lek 2018; 64(3): 232–235.
  13. Lim CT, Kola B, Corbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol 2010; 44(2): 87–97. Dostupné z DOI: <http://dx.doi.org/10.1677/JME-09–0063>.
  14. Łabuzek K, Suchy D, Gabryel B et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010; 62(5): 956–965. Dostupné z DOI: <http://dx.doi.org/10.1016/s1734–1140(10)70357–1>.
  15. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006; 91(1): 225–227. <http://dx.doi.org/10.1210/jc.2005–1210>.
  16. Cappelli C, Rotondi M, Pirola I et al. TSH-lowering effect of metformin in type 2 diabetic patients. Differences between euthyroid, untreated hypothyroid and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32(9): 1589–1590. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–0273>.
  17. Cappelli C, Rotondi M, Pirola I. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 2012; 167(2): 261–265. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12–0225>.
  18. Krysiak R, Gilowska M, Szkróbka W et al. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism. Pharmacol Rep 2016; 68(2): 490–494. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharep.2015.11.010>.
  19. Isidro ML, Penín MA, Nemiña R et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007; 32(1): 79–82. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–007–9012–3>.
  20. Distiller LA, Polakow ES, Joffe BI. Type 2 diabetes mellitus and hypothyroidism: the possible influence of metformin therapy. Diabet Med 2014; 31(2): 172–175. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12342>.
  21. Fournier JP, Yin H, Yu OH et al. Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus. CMAJ 2014; 186(15): 1138–1145. Dostupné z DOI: <http://dx.doi.org/10.1503/cmaj.140688>.
  22. Cappelli C, Rotondi M, Pirola I et al. Metformin-induced thyrotropin suppression is not associated with cardiac effects. Hormones (Athens) 2014; 13(2): 252–258. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03401339>.
  23. Krysiak R, Okopień B. The effect of metformin on the hypothalamic–pituitary–thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism. J Clin Pharmacol 2015; 55(1): 45–49. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.373>.
  24. Krysiak R, Skróbka W, Okopień B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and subclinical hyperthyroidism. Exp Clin Endocrinol Diabetes 2015; 123(4): 205–208. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0034–1398621>.
  25. Krysiak R, Skróbka W, Okopień B. The effect of metformin on hypothalamic-pituitary-thyroid axis activity in women with interferon-induced hypothyroidism: A pilot study. Exp Clin Endocrinol Diabetes 2016; 124(2): 71–76. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0035–1565207>.
  26. Krysiak R, Skróbka W, Okopień B. Sex-dependent effect of metformin on hypothalamic-pituitary-thyroid axis activity in patients with subclinical hypothyroidism. Pharmacol Rep 2016; 68(6): 1115–1119. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharep.2016.07.002>.
  27. Santos-Palacios S, Brugos-Larumbe A, Guillen-Grima F et al. Does metformin have a “buffer effect” on serum TSH levels in euthyroid diabetic patients? Hormones (Athens) 2015; 14(2): 280–285. Dostupné z DOI: <http://dx.doi.org/10.14310/horm.2002.1559>.
  28. Díez JJ, Iglesias P. 2013 Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol 2013; 78(4): 505–511. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2012.04468.x>.
  29. Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 2011; 8(1): 47–48. Dostupné z DOI: <http://dx.doi.org/10.1177/1479164110391917>.
  30. Rotondi M, Cappelli M, Magri F et al. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2011; 75(3): 378–381. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2011.04042.x>.
  31. López M, Varela L, Vázquez MJ et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010; 16(9): 1001–1008. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.2207>.
  32. Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol (Oxf) 2011; 75(1): 1–9. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2011.04029.x>.
  33. Rezzónico J, Rezzónico M, Pusiol E et al. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 2010; 9(1): 69–75. Dostupné z DOI: <http://dx.doi.org/10.1089/met.2010.0026>.
  34. Ittermann T, Markus MRP, Schipf S et al. Metformin inhibits goitrogenous effect of type 2 diabetes. Eur J Endocrinol 2013; 169(1): 9–15. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-13–0101>.
  35. Schipf S, Schmidt CO, Alte D et al. Smoking prevalence in type 2 diabetes: results of the Study of Health in Pomerania and The German National Health Interview and Examination Survey. Diabet Med 2009; 26(8): 791–797. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2009.02784.x>.
  36. Völzke H, Schwahn C, Kohlmann T et al. Risk factors for goiter in a previously iodine-deficient region. Exp Clin Endocrinol Diabet 2005; 113(9): 507–515. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2005–865741>.
  37. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33(7): 1674–1685. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–0666>.
  38. Tseng CH. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes. Ann Med 2013; 45(8): 539–544. Dostupné z DOI: <http://dx.doi.org/10.3109/07853890.2013.851865>.
  39. Chen TM, Lin CC, Huang PT et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2013; 26(5): 858–865. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1440–1746.2011.06664.x>.
  40. Nikkilä EA, Jakobson T, Jokipii SJ et al. Thyroid function in diabetic patients under long-term sulfonylurea treatment. Acta Endocrinol (Copenh) 1960; 33: 623–629. Dostupné z DOI: <http://dx.doi.org/10.1530/acta.0.XXXIII0623>.
  41. Sugrue DD, McEvoy M, Drury MI. Thyroid disease in diabetics. Postgrad Med J 1982; 58(685): 680–684. Dostupné z DOI: <http://dx.doi.org/10.1136/pgmj.58.685.680>.
  42. Kim HK, Yoon JH, Kim SJ et al. Higher TSH level is a risk factor for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2013; 78(3): 472–477. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12027>.
  43. Güney E, Efe B, Akalin A et al. Thyroid Disease in Diabetes Mellitus. Turk J Endocrinol Metab 1999; 3(3): 119–122.
  44. Merkhan MM. The effects of glibenclamide on thyroid function tests in type 2 diabetic patients. Iraq J Pharm 2013; 13(2): 56–61. Dostupné z DOI: <http://dx.doi.org/10.33899/iphr.2013.86556>.
  45. Hu N, Gutsmann A, Herbert DC et al. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994; 9(4): 1021–1027.
  46. Schultes B, Oltmanns KM, Kern W et al. Acute and prolonged effects of insulin-induced hypoglycemia on the pituitary-thyroid axis in humans. Metabolism 2002; 51(10): 1370–1374. Dostupné z DOI: <http://dx.doi.org/10.1053/meta.2002.35193>.
  47. Menaka R, Sehgal M, Lakshmi M et al. Thiazolidinedione precipitated thyroid associated ophthalmopathy. J Assoc Physicians India 2010; 58: 255–257.
  48. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 2014; 11(3–4): 202–230. Dostupné z DOI: <http://dx.doi.org/10.1900/RDS.2014.11.202>.
  49. Wang C. The relationship between type 2 diabetes mellitus and related thyroid diseases. J Diabetes Res 2013; 390534. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/390534>.
  50. Karimifar M, Aminorroaya A, Amini M et al. Effect of metformin on thyroid stimulating hormone and thyroid volume in patients with prediabetes: A randomized placebo-controlled clinical trial. J Res Med Sci 2014; 19(11): 1019–1026.
Labels
Diabetology Obesitology

Article was published in

Diabetes and obesity

Issue 39

2020 Issue 39

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#